Iadademstat is also now being evaluated in combination with paclitaxel in patients with R/R SCLC, with atezolizumab in patients with extensive-stage SCLC and with gilteritinib in patients with R/R FLT3-mutant AML. The gene discussed is FLT3; the disease is small cell lung carcinoma.